Genentech’s Aaron Osborne Joins Adverum as Chief Medical Officer

Adverum Biotechnologies (NASDAQ: [[ticker:ADVM]]) has named Aaron Osborne its chief medical officer. Osborne is joining the Menlo Park, CA, biotech from Roche subsidiary Genentech, where he was principal medical director in product development. His experience also includes senior roles at Alcon and Novartis (NYSE: [[ticker:NVS]]). Adverum’s lead gene therapy candidate, ADVM-022, is in early-stage testing as treatment for the “wet” form of age-related macular degeneration.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.